Crossmark

Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s10194-024-01904-1

Published Online: 2024-11-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Laohapiboolrattana, Wattakorn

Jansem, Priabprat

Anukoolwittaya, Prakit

Roongpiboonsopit, Duangnapa

Hiransuthikul, Akarin

Pongpitakmetha, Thanakit

Thanprasertsuk, Sekh

Rattanawong, Wanakorn
License Information

Text and Data Mining valid from 2024-11-08

Version of Record valid from 2024-11-08
More Information

Article History

Received: 13 October 2024

Accepted: 2 November 2024

First Online: 8 November 2024

Declarations

:

: The ethical approval was not required for this type of study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below